ULK1/2 Kinase Modulation for Mitophagy Induction in Neurodegeneration
📖 Wiki Page
idea1354 wordssynced 2026-04-02
ULK1/2 Kinase Modulation for Mitophagy Induction in Neurodegeneration
Executive Summary
Overview
ULK1/2 kinase modulation represents a promising therapeutic strategy for inducing mitophagy in neurodegenerative diseases. The ULK1/2 complex is a key initiator of mitophagy, the selective [autophagy](/entities/autophagy) of damaged mitochondria. By enhancing ULK1/2 activity, it may be possible to improve mitochondrial quality control in [neurons](/entities/neurons) affected by diseases like [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease). [@ulk2020]
Target: ULK1/2 (Unc-51 Like Autophagy Activating Kinase 1/2) [@small2019]
Approach: Small molecule ULK1/2 activators to enhance mitophagy clearance of damaged mitochondria [@ampkulk2021]
Therapeutic Area: [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [Amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) [@ulk2022]
Score: 78/100
Mechanism of Action
ULK1/2 Biology
[ULK1](/proteins/ulk1-protein) and [ULK2](/proteins/ulk2-protein) are serine/threonine kinases that serve as the master initiators of autophagy and mitophagy. They form a complex with [ATG13](/genes/atg13), [FIP200](/genes/fip200), and [ATG101](/genes/atg101) that responds to cellular energy status (via AMPK) and nutrient sensing (via mTORC1).
...
ULK1/2 Kinase Modulation for Mitophagy Induction in Neurodegeneration
Executive Summary
Overview
ULK1/2 kinase modulation represents a promising therapeutic strategy for inducing mitophagy in neurodegenerative diseases. The ULK1/2 complex is a key initiator of mitophagy, the selective [autophagy](/entities/autophagy) of damaged mitochondria. By enhancing ULK1/2 activity, it may be possible to improve mitochondrial quality control in [neurons](/entities/neurons) affected by diseases like [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease). [@ulk2020]
Target: ULK1/2 (Unc-51 Like Autophagy Activating Kinase 1/2) [@small2019]
Approach: Small molecule ULK1/2 activators to enhance mitophagy clearance of damaged mitochondria [@ampkulk2021]
Therapeutic Area: [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [Amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) [@ulk2022]
Score: 78/100
Mechanism of Action
ULK1/2 Biology
[ULK1](/proteins/ulk1-protein) and [ULK2](/proteins/ulk2-protein) are serine/threonine kinases that serve as the master initiators of autophagy and mitophagy. They form a complex with [ATG13](/genes/atg13), [FIP200](/genes/fip200), and [ATG101](/genes/atg101) that responds to cellular energy status (via AMPK) and nutrient sensing (via mTORC1).
Key downstream effects:
Initiation of autophagosome formation
Recruitment of PI3K complex ([VPS34](/proteins/vps34)/[VPS15](/proteins/vps15))
Phosphorylation of [beclin-1](/proteins/beclin-1) and ATG proteins
Direct phosphorylation of [PINK1](/proteins/pink1-protein) enhancing [Parkin](/proteins/parkin-protein) recruitment
Therapeutic Rationale
In neurodegeneration, mitophagy is consistently impaired:
GLP toxicology studies in rodents and non-human primates
Phase 1 trial design and regulatory pre-IND meeting
Potential Company Partners:
Takeda Neuroscience (co-development)
Biogen (ALS/AD licensing)
AbbVie (Parkinson's licensing)
Denali Therapeutics (delivery expertise)
Phase 3: Clinical Translation (36-48 months)
Timeline: Months 43-90
Estimated Cost: $15-25M
Key Activities:
Phase 1 first-in-human safety study (healthy volunteers)
Phase 2a proof-of-concept in early AD/PD patients
Develop PET ligand for target engagement (optional)
Adaptive dosing based on NfL and mitophagy biomarkers
Regulatory Strategy:
Fast Track designation possible for AD/PD
Use biomarkers (phospho-ULK1, mitophagy flux) for accelerated approval path
Leverage AMPD2/AMPK activator safety data as precedent
Orphan drug designation for rare indications (e.g., ALS)
Risk Assessment
| Risk | Probability | Impact | Mitigation Strategy | |------|-------------|--------|-------------------| | Limited CNS exposure | Medium | High | Use LIT-7000 class with demonstrated BBB penetration | | Off-target kinase effects | Medium | High | Develop ULK1-selective over pan-ULK compounds | | Insufficient efficacy monotherapy | High | Medium | Position as combination therapy backbone with TFEB/NAD+ | | Autophagy dysregulation | Low | Medium | Use intermittent dosing protocol; monitor autophagy biomarkers | | Regulatory delays | Medium | Medium | Pre-IND meeting in Year 1; engage FDA early |
Key Success Metrics
Phospho-ULK1 Ser317 increase in patient neurons (target engagement)
Reduced mitochondrial mass in patient-derived neurons (pharmacodynamics)
No dose-limiting toxicity in Phase 1
≥20% reduction in NfL in Phase 2a
Actionable Next Steps (Next 30 Days)
Contact Dr. Virginia Lee (UPenn) about iPSC neuron collaboration
Request ULK-100 compound samples from Scripps
Draft pre-IND meeting request for FDA
Brief Takeda BD team on co-development opportunity
Risks and Mitigation
| Risk | Mitigation | |------|------------| | Limited CNS exposure | Focus on LIT-7000 class with demonstrated brain penetration | | Off-target kinase effects | Develop ULK1-selective over pan-ULK compounds | | Insufficient efficacy alone | Position as combination therapy backbone | | Autophagy过度 | Use intermittent dosing to maintain homeostasis |
Rubric Score
| Dimension | Score | Rationale | |-----------|-------|-----------| | Novelty | 8/10/10 | ULK1/2 kinase modulation for mitophagy is novel; emerging target | | Mechanistic Rationale | 8/10/10 | ULK1/2 initiates mitophagy; modulation enhances clearance of damaged mitochondria | | Addresses Root Cause | 7/10/10 | Addresses mitochondrial dysfunction - core pathological mechanism | | Delivery Feasibility | 6/10/10 | Small molecule activators in development; brain penetration needs optimization | | Safety Plausibility | 7/10/10 | Autophagy modulation generally well-tolerated; dose control important | | Combinability | 7/10/10 | Synergizes with other autophagy inducers and mitochondrial therapies | | Biomarker Availability | 6/10/10 | Mitophagy markers developing; mitochondrial function biomarkers available | | De-risking Path | 6/10/10 | Early stage; preclinical validation ongoing | | Multi-disease Potential | 8/10/10 | Relevant for AD, PD, ALS, metabolic disorders | | Patient Impact | 7/10/10 | Could enhance mitochondrial quality control | | Total | 70/100 | |
The following diagram shows the key molecular relationships involving ULK1/2 Kinase Modulation for Mitophagy Induction in Neurodegeneration discovered through SciDEX knowledge graph analysis: